C&G Regulatory Guidance with Lineage Cell Therapeutics' Brian Culley

When we last caught up with Brian Culley, CEO of Lineage Cell Therapeutics, it was January 2021. A pandemic was raging. His company was moving mountains to keep its OpRegen dry AMD clinical trial together and did so despite lockdowns that kept a largely aged patient population from setting foot anywhere near a healthcare clinic. On his long-overdue return to the Business of Biotech, Culley opens up on how the company addressed struggling programs, wrestled manufacturing control issues and delivery inefficiencies in its spinal cord program to the ground, and maintained control of its regulatory progress along the way.